These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

Rocket Pharmaceuticals (RCKT) shares plummeted 62.8% to $2.33 after announcing a patient death in the Phase 2 pivotal trial of RP-A501, a gene therapy for Danon disease, due to an acute systemic infection. Consequently, Jefferies downgraded RCKT from Buy to Hold, lowering the price target from $29 to $2.5, while Chardan Capital maintained a Buy rating but significantly reduced its price target from $46 to $17.

Analysis

Rocket Pharmaceuticals (RCKT) experienced a critical setback following the announcement of a patient fatality in its Phase 2 pivotal trial for RP-A501, an investigational gene therapy for Danon disease. The death, attributed to an acute systemic infection and classified as a Serious Adverse Event (SAE), precipitated a severe market response, with RCKT shares plummeting 62.8% to close at $2.33. This adverse event prompted significant revisions from Wall Street analysts: Jefferies downgraded RCKT from Buy to Hold and drastically lowered its price target from $29 to $2.5, reflecting a near-complete reassessment of the asset's value. Chardan Capital, while maintaining a Buy rating, also substantially reduced its price target from $46 to $17, indicating a significantly diminished outlook even with a continued positive stance. The magnitude of the stock's decline and the sharp price target cuts underscore the profound impact of this clinical trial event on the perceived viability of RP-A501 and, consequently, on Rocket Pharmaceuticals' valuation and future prospects.

Key Decisions for Investors

• Investors should acknowledge the heightened risk profile of Rocket Pharmaceuticals following the patient death in the RP-A501 trial, as reflected by the 62.8% share price collapse and significantly lowered analyst price targets.
• Carefully monitor for further updates from the company regarding the status of the RP-A501 trial, regulatory feedback, and any potential implications for the broader gene therapy platform.
• Re-evaluate positions in RCKT considering the deep uncertainty surrounding a key pipeline asset; the Jefferies downgrade to Hold and the substantial price target reduction to $2.5 suggest a significantly impaired near-term outlook, even as Chardan Capital maintains a Buy with a reduced target of $17.